drugset / Trial / NCT04521413
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
Phase 1/2
Active not recruiting
170 enrolled
Treadwell Therapeutics, Inc
TIO Discovery Engine · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Timeline
- Start
- 2020-08-31
- Primary completion
- 2025-11
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CFI-402411 | Unknown | 80 mg | Oral |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |